PARP inhibitorPhase 3 trialInvestigational
Lynparza
Generic name: olaparib
How it works
Blocks an enzyme that helps repair DNA damage, making it harder for cancer cells to grow and survive.
Cancer types
Efficacy
In clinical trials, Lynparza has been shown to improve response rates and progression-free survival in patients with BRCA1/2-mutated ovarian cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Lung Cancer Patients | Lung Cancer | phase-2 | The combination regimen demonstrated an objective response rate of 73.3% and a median overall survival of 14.6 months. | Source → |
| Olaparib Before Surgery for Newly Diagnosed BRCA-Mutant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Olaparib Treatment in Japanese Men with Advanced Prostate Cancer | Prostate Cancer | observational | One-year overall survival rate was 80.6%, with a median overall survival of 18.4 months, and 1-year progression-free survival rate was 27.2% with a median progression-free survival of 7.6 months. | Source → |
| Testing Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib plus bevacizumab may be cost-effective for ovarian cancer patients in China | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib + Abiraterone for Metastatic Prostate Cancer: Real-World Study | Prostate Cancer | preclinical | — | Source → |
| Testing Adavosertib and Olaparib for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Olaparib Before Prostate Cancer Surgery | Prostate Cancer | phase-2 | — | Source → |
| Testing Olaparib and Durvalumab in HER2 Negative BRCAm Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib Before Surgery and Chemotherapy for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Evaluating Combination Therapies for Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combining Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Evaluating a Combination Therapy for Ovarian and Related Cancers | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cirtuvivint and Olaparib in Platinum Resistant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Olaparib and Atezolizumab in BRCA Mutant Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| New Compound Disrupts Cancer Gene Expression | Colorectal Cancer | lab-study | — | Source → |
| Olaparib and Pembrolizumab in Breast Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Studying Olaparib in Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Olaparib with Radium-223 in Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib Study for Patients Who Have Completed Previous Oncology Trials | Breast Cancer | phase-3 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Cediranib and Olaparib Combination Therapy for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing a Combination of Two Drugs for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Ovarian and Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing New Treatments for Women with Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing FPI-2265 and Olaparib for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Prostate Cancer Patient Shows Long-Term Response to New Treatment | Prostate Cancer | observational | To date, his PSA level has remained below 0.001 ng/ml. | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Evaluating Olaparib in Chinese Patients with Advanced Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib for Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Olaparib and Cediranib Combination in Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The combination significantly prolonged progression-free survival (PFS) (overall HR = 0.78; 95% CI: 0.68-0.89; < 0.001). | Source → |
| Rare Cancer Treated with Targeted Therapy | Lung Cancer | observational | — | Source → |
| Researchers Identify New Target to Enhance Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Curcumin Analogue and Olaparib Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
| TTK protein linked to resistance in ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Combining Cancer Treatments May Help Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Boosts Immune Response in Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Olaparib Monotherapy Shows Promise in Lung Cancer Treatment | Lung Cancer | meta-analysis | Olaparib monotherapy increased progression-free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Olaparib Therapy Side Effects in UAE Patients | Breast Cancer | observational | — | Source → |
| Olaparib vs Nonplatinum Chemotherapy in Ovarian Cancer | Ovarian Cancer | phase-3 | Overall survival with olaparib was similar to chemotherapy (median 34.9 and 32.9 months, respectively). | Source → |
| Combining drugs may improve ovarian cancer treatment | Ovarian Cancer | lab-study | The combined treatment allows a substantial dose reduction of olaparib rendering a strong synergistic effect. | Source → |
| Olaparib Maintenance Therapy Shows Promise in Ovarian Cancer | Ovarian Cancer | observational | The 1-year progression-free survival rate was 75.2% (95% CI, 63.4 to 89.2), and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). | Source → |
| Combining Cancer Drugs May Improve Treatment for Advanced Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Lung Disease Linked to Cancer Treatment | Breast Cancer | observational | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| gBRCA Testing and Olaparib in Pancreatic Cancer | Pancreatic Cancer | observational | The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). | Source → |
| Combination Cediranib and Olaparib Shows Activity in Ovarian Cancer | Ovarian Cancer | phase-2 | In platinum-sensitive ovarian cancer, the overall response rate was 77.1% and median progression-free survival was 16.4 months. | Source → |
| Olaparib Maintenance Therapy in Ovarian Cancer: Biomarker Analysis | Ovarian Cancer | phase-3 | HRD-positive patients displayed greater median PFS [17.9 months (95% CI: 14.5-22.1)] than HRD-negative patients [9.2 months (95% CI: 7.5-13.8)]. | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer: A Study at Kurume University Hospital | Ovarian Cancer | observational | The median progression-free survival was 8.9 months, and the median overall survival was 27.1 months. | Source → |
| Pancreatic Cancer Treatment Shows Promise in Rare Genetic Case | Ovarian Cancer | observational | — | Source → |
| CRABP2 May Reduce Effectiveness of Cancer Treatment Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Inhibiting FSP1 Enhances Olaparib Sensitivity in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Olaparib and Niraparib Maintenance Treatments for Ovarian Cancer | Ovarian Cancer | phase-2 | The median progression-free survival of 117 patients was 20.1 months. | Source → |
| Combining Olaparib and CDK12-IN-3 to Treat Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Possible Cause of Cancer Treatment Resistance | Pancreatic Cancer | lab-study | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| Combining drugs may help overcome resistance to ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Measuring PARP Inhibitors in Ovarian Cancer Patients | Ovarian Cancer | lab-study | — | Source → |
| Olaparib Therapy in Ovarian Cancer: New Predictor Identified | Ovarian Cancer | phase-2 | The median progression-free survival was 12 months. | Source → |
| PARP Inhibitors May Work Better in Prostate Cancer When Combined with Other Treatment | Prostate Cancer | lab-study | — | Source → |
| Olaparib plus Bevacizumab May Be Cost-Effective for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| Combining Two Cancer Drugs Shows Promise in Resistant Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 50% (95% confidence interval, 0.15-0.72). | Source → |
| Predicting Breast Cancer Response to Olaparib with Mathematical Models | Breast Cancer | lab-study | — | Source → |
| Olaparib Monotherapy for Ovarian Cancer: Factors Affecting Survival | Ovarian Cancer | observational | — | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer Patients | Ovarian Cancer | observational | Among patients with partial remission from most recent chemotherapy, 3 (3.84%) showed complete response and 6 (7.69%) showed partial response. | Source → |
| Olaparib Can Be Re-Administered After Chemotherapy | Breast Cancer | observational | — | Source → |
| Olaparib Use in Ovarian Cancer Patients with End-Stage Renal Disease | Ovarian Cancer | lab-study | This maintenance therapy led to 16 months of progression free survival. | Source → |
| Olaparib Extends Life Without Symptoms for Pancreatic Cancer Patients | Pancreatic Cancer | phase-3 | TWiST was significantly longer for olaparib than placebo in the base-case analysis (14.6 vs 7.1 months; 95% CI, 2.9-12.0; p = .001) | Source → |
| Olaparib Efficacy in Relapsed Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 17.0 months. | Source → |
| mA reader HNRNPA2B1's role in breast cancer cell growth and response to treatment | Breast Cancer | lab-study | Downregulation of HNRNPA2B1 partially reversed de novo resistance to olaparib in breast cancer. | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Combining Olaparib and Radiotherapy for Triple-Negative Breast Cancer | Breast Cancer | phase-1 | Three-year overall survival was 83% (95% CI, 70%-100%) and event-free survival was 65% (95% CI, 48%-88%). | Source → |
| Olaparib and Bevacizumab Benefit High-Grade Ovarian Cancer Patients with BRCA Mutations | Ovarian Cancer | phase-3 | The 24-month PFS rate was estimated to be 89% and 15% for patients with BRCA1m located in the DBD, with a hazard ratio of 0.08 (olaparib + bevacizumab versus placebo + bevacizumab). | Source → |
| Olaparib treatment in pancreatic cancer patients with BRCA2 mutation | Pancreatic Cancer | observational | The patient remained 10 months on olaparib treatment, without disease progression. | Source → |
| Combining Olaparib and Arsenic Trioxide May Help Treat Platinum-Resistant Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Desensitization Method for Allergic Reactions to Cancer Drug Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Drugs May Improve Ovarian Cancer Treatment | Ovarian Cancer | lab-study | The combination index (CI) values partially show synergisms in combinations at 100 nM and 500 nM P8-D6. | Source → |
| Olaparib Shows Promise in Asian Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Radiographic progression-free survival (rPFS) favored olaparib versus control in Cohort A [rPFS 7.2 vs. 4.5 months, HR 0.58, 95% CI 0.29-1.21]. | Source → |
| Combining Oleanolic Acid and Olaparib Enhances Radiotherapy in Triple Negative Breast Cancer | Breast Cancer | lab-study | The sensitization enhancement ratios (SER) were 1.16-1.65. | Source → |
| Rare skin side effect reported in patient taking olaparib for ovarian cancer | Ovarian Cancer | observational | — | Source → |
| PARP Inhibitor Use in Gynecological Cancer Patients Compared | Ovarian Cancer | observational | — | Source → |
| Tumor Genomic Testing for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Olaparib Maintenance Treatment for Ovarian Cancer in Chinese Patients | Ovarian Cancer | phase-3 | Olaparib treatment led to an improvement in progression-free survival compared with placebo (hazard ratio = 0.44, 95% confidence interval: 0.17-1.19; median = 13.8 vs. 5.5 months). | Source → |
| Olaparib's Safety for Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Olaparib Monotherapy Shows Promise in Advanced Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer Patients | Ovarian Cancer | phase-3 | Median progression-free survival was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. | Source → |
| New Compound Sensitizes Ovarian Cancer to Treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib and Bevacizumab Combination Extends Progression-Free Survival in Ovarian Cancer | Ovarian Cancer | phase-3 | Olaparib plus bevacizumab provided a substantial PFS benefit versus bevacizumab alone in the homologous recombination deficiency (HRD)-positive subgroup, with a 61% reduction of risk of progression or death in the higher-risk group and an 85% reduction in the lower-risk group. | Source → |
| Combining two drugs may slow pancreatic cancer growth | Pancreatic Cancer | lab-study | — | Source → |
| Combining two cancer drugs may improve treatment for ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Drugs May Improve Treatment for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Two Drugs Shows Promise in Treating Ovarian Cancer | Ovarian Cancer | animal-study | The combination yielded significantly lower tumor weight and fewer tumor nodules compared with the control group (< 0.04 and < 0.03 in the A2780luc ip1 mouse model, and = 0.006 and = 0.059 in the OVCAR5 mouse model). | Source → |
| Olaparib Extends Survival in Some Breast Cancer Patients | Breast Cancer | phase-3 | The 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group. | Source → |
| Olaparib Monotherapy Effective in Some Breast Cancer Patients | Breast Cancer | phase-3 | The median investigator-assessed progression-free survival was 8.11 months. | Source → |
| Olaparib Treatment for Ovarian Cancer: A Case Study | Ovarian Cancer | observational | — | Source → |
| New Uses for PARP Inhibitors in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.